Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: February

. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...

Right Turn: No horsing around with this grand gesture

. American media and telecom billionaire John Malone, along with his horse-breeding wife Leslie, have generously donated U.S. $42.5 million to Colorado State University to launch the CSU Institute for Biologic Translational Therapies to develop regenerative medicine...

Cell Therapy 2.0 – warts and all

> The last 15 years of stem cell research have been full of hope and promises – some of it delivered upon, most of it not quite there yet, and some of it miserably failed. I guess that is to be expected in a highly experimental area of medicine, but one of the most...

Hot off the press: DNA-based bioprinting of tissues

. By S. Amanda Ali, PhD What do biomaterials mean to you? For this orthopaedic scientist, the first thing that comes to mind is the total joint replacement: artificial knees, hips and shoulders made from a variety of materials to reproduce joint function and suit each...

Right Turn: Commercializing iPSCs – Infographics

. The beauty of an infographic (or two) is it speaks for itself.   Shared with permission of BioInformant: http://www.bioinformant.com/   Our regular feature, Right Turn, appears every Friday and we invite you to submit your own blog to info(at)ccrm.ca. We...

Regenerative Medicine Deal Review: January

. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck...